Effect of SGLT2 inhibitors versus DPP4 inhibitors on major and non-major osteoporotic fracture risks among general and high-risk type 2 diabetes patients: A nationwide retrospective cohort study
CONCLUSION: - This study adds supporting real-world evidence for SGLT2is-associated bone safety for a wide range of fractures, which promotes the rational use of SGLT2is in routine care and highlights the importance of the close monitoring of patients with high fracture risks to maximize treatment benefits while reducing undesirable effects.PMID:37451539 | DOI:10.1016/j.diabet.2023.101465
Source: Diabetes and Metabolism - Category: Endocrinology Authors: Zi-Yang Peng Yao-Tseng Wang Chin-Sung Chang Chih-Hsing Wu Huang-Tz Ou Source Type: research
More News: Databases & Libraries | Diabetes | Diabetes Type 2 | Endocrinology | Health Insurance | Insurance | Orthopaedics | Osteoporosis | SGLT2 Inhibitors | Sodium | Study | Taiwan Health